# To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

> **NCT04551053** · PHASE3 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 177 (actual)

## Conditions studied

- Myelofibrosis
- Primary Myelofibrosis
- Post Essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis

## Interventions

- **DRUG:** parsaclisib
- **DRUG:** ruxolitinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04551053
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-26
- **Primary completion:** 2023-08-16
- **Final completion:** 2024-08-21
- **Target enrollment:** 177 (ACTUAL)
- **Why stopped:** The study was terminated due to futility.
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551053, "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04551053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*